1. Home
  2. NVCR vs NNNN Comparison

NVCR vs NNNN Comparison

Compare NVCR & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$13.57

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$34.00

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVCR
NNNN
Founded
2000
2021
Country
Switzerland
Germany
Employees
N/A
27
Industry
Medical/Dental Instruments
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2015
2025

Fundamental Metrics

Financial Performance
Metric
NVCR
NNNN
Price
$13.57
$34.00
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$28.42
N/A
AVG Volume (30 Days)
1.8M
37.8K
Earning Date
10-30-2025
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
$642,269,000.00
$8,185,146.00
Revenue This Year
$9.75
N/A
Revenue Next Year
$5.62
N/A
P/E Ratio
N/A
$619.66
Revenue Growth
11.17
21.95
52 Week Low
$10.70
$5.18
52 Week High
$32.06
$55.65

Technical Indicators

Market Signals
Indicator
NVCR
NNNN
Relative Strength Index (RSI) 59.44 54.45
Support Level $12.30 $31.18
Resistance Level $13.97 $35.55
Average True Range (ATR) 0.55 5.14
MACD 0.09 0.14
Stochastic Oscillator 77.21 37.79

Price Performance

Historical Comparison
NVCR
NNNN

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: